A new BET on the control of HIV latency.
Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, OH, USA. jonathan.karn@case.edu
Jonathan
J
Karn
D018797:Cell Cycle Proteins; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D009687:Nuclear Proteins / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism*; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000378:metabolism*; D000092468:Bromodomain Containing Proteins
D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D017346:Protein Serine-Threonine Kinases; D014157:Transcription Factors; D054322:tat Gene Products, Human Immunodeficiency Virus; C098415:BRD2 protein, human; D000092468:Bromodomain Containing Proteins; C441289:BRD4 protein, human
BET proteins; BRD2; BRD4; E2F1; HIV latency; JQ1; P-TEFb